SWK Holdings ( (SWKH) ) just unveiled an update.
On March 19, 2025, SWK Holdings Corporation announced the monetization of its royalty portfolio through two transactions. ANI Pharmaceuticals exercised its buyout option on March 17, 2025, resulting in a $17.3 million payment to SWK. Additionally, SWK entered into an agreement with Soleus Capital to sell its remaining performing royalty portfolio for $34.0 million. The combined transactions total approximately $51.3 million, exceeding the portfolio’s book value by $1.0 million. SWK plans to use part of the proceeds for a cash dividend to shareholders, with details to be announced upon closing. This move underscores SWK’s strategy to realize asset value and potentially benefit stakeholders.
More about SWK Holdings
SWK Holdings Corporation is a life science-focused specialty finance company that partners with small- and mid-sized commercial-stage healthcare companies. The company provides non-dilutive financing to support the development and commercialization of medical technologies and products, offering structured debt, royalty monetization, synthetic royalty transactions, and asset purchases. SWK also owns Enteris BioPharma, a clinical development and manufacturing organization.
YTD Price Performance: 2.50%
Average Trading Volume: 6,949
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $194.6M
See more insights into SWKH stock on TipRanks’ Stock Analysis page.